Third Party Manufacturing Pharma Africa: PCD, Private Label & Contract Manufacturing Explained
Four business models get lumped under one label. Here’s what actually separates them — and which one fits your business.
Before publishing: this draft avoids inventing market-size, growth-rate, or pricing figures. Anywhere a statistic about the African pharmaceutical market, PCD franchise sector size, or contract manufacturing growth rate would strengthen a section, insert a current figure from a sourced, citable reference (e.g. WHO, IQVIA, or a recent industry report) and link it. Do not publish placeholder or estimated numbers as fact.
Search for third party manufacturing pharma Africa and you’ll find dozens of pages using the phrase as a catch-all for four distinct business models — each with different ownership rights, minimum order quantities, and capital requirements. Conflating them is the single most common reason African importers and pharma entrepreneurs end up in agreements that don’t match what they actually needed.
This guide picks the four models apart precisely and tells you what to check before you sign anything. If you’re still deciding whether to manufacture through a partner at all or import finished, registered product directly, read Pharmaceutical Export to Africa: The Complete Guide for Importers & Distributors first — this page picks up where that one leaves off, and the same trade-off gets a fuller side-by-side treatment in our Third-Party Manufacturing vs. Direct Sourcing comparison. (Confirm the Pillar 1 URL matches its live slug before publishing.)
Third Party Manufacturing Pharma Africa: What the Term Actually Covers
“Third-party manufacturing” is an umbrella term for any arrangement where a pharmaceutical business doesn’t run its own factory but has a licensed manufacturer produce its products instead. That’s the only thing every version of this arrangement has in common. Beyond it, the models diverge sharply on who owns the formulation, who owns the brand, how large a single order has to be, and how quickly you can actually get product into a market.
The confusion happens because Indian pharma marketing material — B2B directories, trade-show banners, WhatsApp pitches — uses “third-party manufacturing,” “contract manufacturing,” “private label,” “white label,” and “PCD franchise” almost interchangeably. They aren’t. Four distinct models sit under that one label: contract manufacturing, private label / white label, PCD franchise, and custom formulation development — each covered in detail below. A PCD franchise holder distributing into Ghana and a private label brand owner launching in Kenya are running two structurally different businesses, even though both might describe what they do as “third-party manufacturing.”
The distinctions below aren’t academic. They determine how much capital you need upfront, whether you own anything you can sell or transfer later, and how exposed you are if the relationship with your manufacturer ends.
Contract Manufacturing
Definition
Contract manufacturing pharma India arrangements work like this: the brand owner supplies or approves a formulation and a master specification, and a WHO-GMP contract manufacturer produces the finished product to those exact specs, then packs and labels it under the brand owner’s name. The brand owner typically holds rights to the formulation and carries responsibility for registering the product in each destination market. The manufacturer’s job is production, in-process quality control, and batch documentation — not brand strategy or market entry.
Who it suits
Importers and distributors who already have products registered — or in active registration — in specific African countries, have an established brand identity, and need dependable bulk manufacturing pharma India capacity without capital-heavy factory ownership. This is the model for businesses planning a multi-year brand presence and ordering at real volume, not testing the water with a small batch. See our contract manufacturing services for how this runs in practice. (Confirm this Services page URL before publishing.)
What sets it apart
Full formulation control if it’s written into the agreement, the highest typical minimum order quantities of the three core models, and the longest lead time whenever registration or dossier work is still pending in the destination country. It’s also the model with the highest upfront cost, largely because of registration expenses and larger batch commitments.
Private Label & White Label Manufacturing
Definition
A private label pharmaceutical manufacturer India works from a different starting point: the buyer selects from the manufacturer’s existing, already-developed and often already-registered product range, then applies their own brand name, trademark, and pack design to it. The underlying formulation stays the manufacturer’s — you’re customizing presentation, not chemistry. White label pushes this further: an identical, unmodified product sold under several different buyers’ brand names at once, with even less room to request formulation tweaks than private label allows.
Who it suits
New entrants planning a pharmaceutical brand launch Africa-wide who want their own product line fast, without R&D spend or dossier-development timelines, by using formulations the white label medicine manufacturer has already stabilized and, in many cases, already has registration templates for.
What sets it apart
A MOQ private label medicine order is usually well below contract manufacturing volumes, because the manufacturer is already producing the item at scale for other clients too — see our dedicated guide on MOQ, packaging & shipping for typical numbers. Time to market is fast — typically the second-fastest of the four models, behind only PCD franchise. What you don’t get is ownership of the underlying formula: if you switch manufacturers later, you generally can’t take “your” formulation with you, because it was never yours to begin with. Own brand medicine manufacturing India arrangements of this kind are worth entering with that limitation clearly understood.
PCD Pharma Franchise
Definition
PCD stands for Propaganda Cum Distribution. A PCD pharma franchise Africa arrangement is a monopoly-based marketing and distribution model — not a manufacturing model at all. The manufacturer retains the product, the brand name, and the formulation. The franchise holder buys finished, already-branded stock and receives exclusive marketing and distribution rights across a defined territory: a country, a region, or a set of African markets, depending on what’s negotiated. The franchisee’s business is sales and distribution, not production or even brand-building, though many agreements do let them trade under their own business name on invoices and promotional material even while the product itself carries the parent brand.
Who it suits
Individuals and small businesses starting a pharma franchise business Africa venture for the first time, with limited capital, who want to build on an already-registered, already-manufactured product line without any factory involvement or formulation cost.
What sets it apart
The lowest MOQ, the lowest upfront investment, and the fastest time to market of any of the four models — but also the least control over branding and product range. You’re building distribution equity here, not brand equity, unless the specific agreement grants trademark or brand-transfer rights, which is uncommon in this model.
Custom Formulation Development — A Related but Distinct Service
Definition
Custom formulation manufacturing is an R&D service, not a manufacturing or distribution model in its own right. A manufacturer’s technical team develops a new formulation — a specific combination, strength, dosage form, or delivery mechanism — to the client’s brief, rather than pulling something off an existing catalogue. It covers formulation trials, stability studies, and compiling the technical dossier a registration will eventually need.
Why it’s a separate category
Custom formulation development is a phase that feeds into contract manufacturing once the work is done — the client typically owns or controls the resulting formulation and then has it manufactured under a standard contract manufacturing agreement. It isn’t, by itself, a route to market; it’s the R&D stage that makes a genuinely differentiated product possible, most often used for country-specific combination products or dosage forms that don’t already exist in a manufacturer’s portfolio.
Who it suits
Brand owners who need something that isn’t sitting in any manufacturer’s current catalogue — a specific combination therapy required by a particular African market’s treatment protocol, for example, or a dosage form no existing supplier offers.
Timeline note
This is usually the longest lead time of any service on this page, often several months, because formulation trials and stability data have to be completed before commercial-scale production can even begin.
What to Expect in a Manufacturing Agreement
Documentation
Expect a Manufacturing/Supply Agreement (or a Franchise Agreement for PCD arrangements) that spells out territory, exclusivity, and minimum order commitments; a product specification sheet signed by both parties; a current WHO-GMP certificate covering the specific manufacturing site and dosage form; a Certificate of Pharmaceutical Product (CoPP) issued by India’s Central Drugs Standard Control Organisation (CDSCO), which most African countries require for import registration; a Free Sale Certificate; and a batch-wise Certificate of Analysis for every shipment. Where a custom formulation is involved, add a separate development or technology-transfer agreement that spells out IP ownership.
Timelines
For private label and PCD orders, the clock runs from order confirmation to shipment-readiness — often a matter of weeks, since formulation and packaging artwork already exist. For contract manufacturing that involves new registration, or private label with custom packaging design, add time for artwork approval and, on a first order from a new manufacturer, first-batch documentation review. For custom formulation work, extend the timeline further to include formulation trials and, where required, stability studies before the first commercial batch is even possible.
Quality responsibilities
Get it in writing: who tests each batch before release — manufacturer QC, an independent third-party lab, or both — what specification the batch is tested against, and what happens if a batch fails: replacement, refund, or renegotiation. In many African markets the importer, not the manufacturer, carries legal responsibility for the product once it clears customs, which makes this allocation of responsibility worth scrutinizing rather than assuming. Continent-wide harmonization efforts through the African Medicines Agency are gradually simplifying multi-country registration, but until a product is covered by that process, treat each country’s national authority as a separate approval to plan for.
Common Mistakes African Entrepreneurs Make When Choosing a Manufacturing Partner
Treating “PCD franchise” and “private label” as interchangeable, then being surprised that a PCD agreement grants no brand or formulation ownership at all.
Not checking whether a manufacturer’s WHO-GMP certificate actually covers the specific dosage form and manufacturing block being quoted — a site certificate doesn’t automatically cover every product line made there.
Ordering below the minimum viable batch size for a given formulation, which affects per-unit pricing and can, in some cases, push a manufacturer to cut corners on non-critical process steps just to make a small order economical.
Assuming an Indian export or manufacturing license automatically satisfies the destination country’s import and registration requirements. Most African regulatory authorities require their own registration dossier regardless of what’s approved for export from India.
Not clarifying, before signing, who retains rights to the formulation and dossier if the relationship ends. This matters most in contract manufacturing and custom formulation — there was never any ownership to transfer in a classic PCD arrangement.
Under-budgeting the timeline for custom formulation work, then locking in a launch date before stability data is even complete.
Checklist: Questions to Ask Before Signing a Manufacturing Agreement
Click each item as you confirm it with a prospective manufacturing partner.
